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We established a mouse model of microenvironment-dependent human lymphoma, and assessed the therapeutic potential of
bevacizumab, an antitumor agent acting on the microenvironment. NOD/Shi-scid, IL-2Rg
null (NOG) mice were used as recipients
of primary tumor cells from a patient with diffuse large B-cell lymphoma (DLBCL), which engraft and proliferate in a
microenvironment-dependent manner. The lymphoma cells could be serially transplanted in NOG mice, but could not be
maintained in in vitro cultures. Injection of bevacizumab together with CHOP (cyclophosphamide, doxorubicin, vincristine,
prednisolone) signiﬁcantly increased necrosis and decreased vascularization in the tumor, compared with CHOP alone. Levels of
human soluble interleukin-2 receptor (sIL2R) in the serum of bevacizumabþCHOP-treated mice (reﬂecting the DLBCL tumor
burden) were signiﬁcantly lower than in CHOP recipients. Mice receiving bevacizumab monotherapy also showed signiﬁcant
beneﬁt in terms of tumor necrosis and vascularization, as well as decreased serum sIL2R concentrations. The present DLBCL model
reﬂects the human DLBCL in vivo environment more appropriately than current mouse models using established tumor cell lines.
This is the ﬁrst report to evaluate the efﬁcacy of bevacizumab in such a tumor microenvironment-dependent model. Bevacizumab
may be a potential treatment strategy for DLBCL patients.
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INTRODUCTION
Tumors develop in a complex and dynamic microenvironment.
Surrounding or within the tumor nests, stromal cells, endothelial
cells, innate immune cells and other lymphocytes are present that
interact with each other and with the tumor cells. A large body of
evidence has accumulated in the past decade demonstrating that
this complex tumor microenvironment regulates tumor growth,
invasion, and metastasis.
1 Angiogenesis is one of the most
important phenomena within the tumor microenvironment;
cancer cells have the ability to recruit and generate new
blood vessels through the secretion of angiogenic factors.
Tumor angiogenesis ensures that cells in the interior of
the tumor receive sufﬁcient nutrients and oxygen to survive.
Blocking tumor angiogenesis would therefore severely restrict
tumor growth.
2 Early experiments using mouse xenografts
indicated that antibody-mediated inhibition of vascular
endothelial growth factor (VEGF), which promotes the
proliferation and migration of vascular endothelial cells and
vessel sprouting, could severely inhibit angiogenesis and tumor
growth.
3 These and other studies led to the development of the
anti-VEGF neutralizing antibody bevacizumab for therapeutic use.
4
However, a current crucial problem in the research ﬁeld of anti-
tumor microenvironment agents such as bevacizumab is the lack
of suitable small animal models. To the best of our knowledge, all
preclinical testing of the antitumor activity of bevacizumab
in mice in vivo has been performed using established tumor
cell lines, which by deﬁnition can be maintained in vitro in culture.
Such tumor cells have thus been selected for survival in the
absence of any microenvironment, including the vascular
system. Using these established lines in mouse xenograft
models therefore seems less relevant for the evaluation of the
antitumor activities of anti-angiogenesis agents. Hence, the ﬁrst
objective of the present study was to overcome this problem. We
aimed to establish a mouse model in which primary tumor cells
from a patient engraft and proliferate in a microenvironment-
dependent manner, using NOD/Shi-scid, IL-2Rg
null (NOG) mice as
recipients.
5,6
Bevacizumab is currently approved world-wide for the treat-
ment of several types of solid tumors such as colorectal cancer,
breast cancer, non-small cell lung cancer, renal cell cancer and
glioblastoma.
7–15 Many aspects of pathological angiogenesis have
been extensively studied in many types of solid tumors. However,
the precise role of these processes in pathogenesis of
hematological malignancies is still under active investigation,
and in this context, bevacizumab is not currently approved for the
treatment of hematological malignancies in the United States,
Europe, or Japan. Thus, the second aim of the present study was
to evaluate the therapeutic potential of bevacizumab with or
without systemic chemotherapy for hematological neoplasia,
using newly established primary tumor cell-bearing NOG mice.
We selected diffuse large B-cell lymphoma (DLBCL) as the target
disease because this represents the most common type of
malignant lymphoma and accounts for B30–40% of all cases in
adults.
16,17
1Department of Medical Oncology and Immunology, Nagoya City University Graduate School of Medical Sciences, 1 Kawasumi, Mizuho-chou, Mizuho-ku, Nagoya, Aichi, Japan
and
2Department of Clinical Pathology, Nagoya City University Graduate School of Medical Sciences, 1 Kawasumi, Mizuho-chou, Mizuho-ku, Nagoya, Aichi, Japan.
Correspondence: Dr T Ishida, Department of Medical Oncology and Immunology, Nagoya City University Graduate School of Medical Sciences, 1 Kawasumi, Mizuho-chou,
Mizuho-ku, Nagoya, Aichi 467-8601, Japan.
E-mail: itakashi@med.nagoya-cu.ac.jp
Received 17 February 2012; revised 29 February 2012; accepted 21 March 2012
Citation: Blood Cancer Journal (2012) 2, e67; doi:10.1038/bcj.2012.12
& 2012 Macmillan Publishers Limited All rights reserved 2044-5385/12
www.nature.com/bcjMATERIALS AND METHODS
Animals
NOG mice were purchased from the Central Institute for Experimental
Animals (Kanagawa, Japan) and used at 6–8 weeks of age. All of the in vivo
experiments were performed in accordance with the United Kingdom
Coordinating Committee on Cancer Research Guidelines for the Welfare of
Animals in Experimental Neoplasia, Second Edition, and were approved by
the Ethics Committee of the Center for Experimental Animal Science,
Nagoya City University Graduate School of Medical Sciences.
Immunopathological analysis
We assessed the affected lymph nodes of 50 patients with DLBCL by
immunopathology. The patients provided written informed consent in
accordance with the Declaration of Helsinki, and the present study was
approved by the institutional Ethics Committee of Nagoya City University
Graduate School of Medical Sciences. Hematoxylin and eosin staining and
immunostaining using anti-human CD20 (L26; DAKO, Glostrup, Denmark),
CD25, (4C9; Novocastra, Wetzlar, Germany), CD3 (SP7; SPRING BIOSCIENCE,
Pleasanton, CA, USA), VEGF-A (sc-152, rabbit polyclonal, Santa Cruz,
Heidelberg, Germany), Alpha-Smooth Muscle Actin (a-SMA; 1A4; DAKO),
von Willebrand Factor (Rabbit polyclonal, DAKO), CD31 (JC70A, DAKO),
CD10 (56C6; Novocastra), BCL-6 (LN22; Novocastra) and MUM1/IRF4 (M-17,
Santa Cruz) were performed on formalin-ﬁxed, parafﬁn-embedded
sections. The presence of Epstein-Barr virus encoded RNA (EBER) was
examined by in situ hybridization using EBER Probe (Leica microsystems,
Newcastle, UK) on formalin-ﬁxed, parafﬁn-embedded sections. DLBCL
cases were categorized into germinal center B-cell (GCB) or non-GCB
phenotypes using formalin-ﬁxed, parafﬁn-embedded sections according to
Hans’ Algorithm.
18 VEGF-A expression levels were categorized according to
the following formula: 3þ positive ifX50%, 2þ positive ifo50X30%, 1þ
positive ifo30X10% and negative ifo10% of the DLBCL tumor cells were
stained with the corresponding antibody. Nine  100 high-power ﬁelds
(HPF) of hematoxylin and eosin tumor specimens were randomly selected
and the area of tumor necrosis (%) was calculated by Image J software
19
and then averaged. Nine  100 HPF of von Willebrand Factor-stained
tumor specimens were randomly selected and the numbers of vessels
(per mm
2) were calculated by Image J software
19 and then averaged.
Primary DLBCL cell-bearing mouse model
The affected lymph node cells from a patient with DLBCL were suspended
in RPMI-1640. The tumor cell donor provided written informed consent
before sampling in accordance with the Declaration of Helsinki, and the
present study was approved by the institutional Ethics Committee of
Nagoya City University Graduate School of Medical Sciences. CD3-negative
subsets were isolated using anti-human CD3 microbeads (Miltenyi Biotec,
Bergisch Gladbach, Germany) and the autoMACS Pro Separator (Miltenyi
Biotec) according to the manufacturer’s instructions. Immunopathological
analysis of the patient’s affected lymph node revealed that the DLBCL type
was non-GCB (CD10 , BCL-6  and MUM1/IRF4þ), and VEGF expression
was 1þ positive. Six to 8 weeks after intraperitoneal (i.p.) injection, NOG
mice presented with i.p. masses and splenomegaly. Cells from these i.p.
masses were suspended in RPMI-1640 and i.p. inoculated into other
NOG mice, which then presented with features identical to those of the
ﬁrst mice.
DLBCL cell lines
DB and HT were purchased from DSMZ (Braunschweig, Germany).
KARPAS422, OCI-LY19, Farage, Toledo, Pfeiffer and RL were purchased
from ATCC (Manassas, VA, USA).
Quantitative reverse transcription PCR
Total RNA was isolated with RNeasy Mini Kit (QIAGEN, Tokyo, Japan).
Reverse transcription from the RNA to ﬁrst strand cDNA was carried out
using High Capacity RNA-to-cDNA Kit (Applied Biosystems Inc., Foster City,
CA, USA) according to the manufacturer’s instructions. Human VEGF-A
(Hs00900055_m1), VEGF-R1 (Hs00176573_m1), VEGF-R2 (Hs00911700_m1)
and b-actin (Hs99999903_m1) mRNA were ampliﬁed using TaqMan Gene
Expression Assays with the aid of an Applied Biosystems StepOnePlus
according to the manufacturer’s instructions. The quantitative assessment
of the mRNA of interest was done by dividing its level by that of b-actin
and expressing the result relative to Human Testis Total RNA (Clontech,
Mountain View, CA, USA) as 1.0. All expressed values were averages of
triplicate experiments.
Monoclonal antibodies and ﬂow cytometry
The following monoclonal antibodies (mAbs) were used for ﬂow
cytometry: MultiTEST CD3 (clone SK7) FITC/CD16 (B73.1)þCD56 (NCAM
16.2) PE/CD45 (2D1,) PerCP/CD19 (SJ25C1) APC Reagent (BD Biosciences,
San Jose, CA, USA), PerCP-conjugated anti-human CD45 mAb (2D1,
BD Biosciences), APC-conjugated anti-CD19 mAb (HIB19, BD Biosciences),
PE-conjugated anti-CD25 mAb (M-A251, BD Biosciences), PE-conjugated
VEGF-R1 mAb (49560, BD Biosciences), PE-conjugated VEGF-R2 mAb
(89106, R&D Systems Inc., Minneapolis, MN, USA) and the appropriate
isotype control mAbs. Whole blood cells from mice were treated with BD
FACS lysing solution (BD Biosciences) for lysing red blood cells . Cells were
analyzed by a FACSCalibur (BD Biosciences) with the aid of FlowJo software
(Tree Star Inc., Ashland, OR, USA).
Cell proliferation assay
Proliferation of the DLBCL cell lines, which express both VEGF-A and
VEGF-R in the presence of different concentrations of bevacizumab
for 48h, was assessed using the CellTiter 96 Aqueous One Solution cell
proliferation assay kit (Promega Corporation, Madison, WI, USA) as
described previously.
20 Proliferation of the NOG DLBCL cells with or
without human interleukin-2 at a ﬁnal concentration of 100IU/ml was also
assessed in the same manner.
Primary DLBCL cell-bearing mice treated with
CHOPþbevacizumab
Tumor cells from the i.p. masses were suspended in RPMI-1640, and
1.0 10
7 were i.p. inoculated into each of 10 NOG mice. The mice were
divided into two groups of ﬁve each for treatment with bevacizumabþ
CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone) or CHOP
alone, 2 days after tumor inoculation. Bevacizumab (10mg/kg) or control
(saline) was i.p. injected into the mice 2, 9, 16, 23, 30, 37 and 44 days
after tumor cell inoculations. CHOP was given i.p. 30 days after
tumor inoculations at doses as follows: cyclophosphamide, 40mg/kg;
doxorubicin, 3.3mg/kg; vincristine, 0.5mg/kg; prednisolone, 0.2mg/kg.
21
Therapeutic efﬁcacies were evaluated 49 days after tumor inoculation.
Bevacizumab was purchased from Chugai Pharmaceutical Co., Ltd, Tokyo,
Japan; cyclophosphamide and vincristine were purchased from Shionogi
Pharmaceutical Co., Ltd, Osaka, Japan; doxorubicin was from Kyowa Hakko
Kirin Co., Ltd, Tokyo, Japan and prednisolone was from Nippon Kayaku Co.,
Ltd, Tokyo Japan.
Primary DLBCL cell-bearing mice treated with bevacizumab
A total of 1.0 10
7 tumor cells were i.p. inoculated into each of 18 NOG
mice, divided into two groups of nine each for bevacizumab or control.
Bevacizumab (10mg/kg) or control (saline) was i.p. injected into the mice
after 3, 10, 17, 24, 31, 38 and 45 days, and therapeutic efﬁcacies were
evaluated 47 days after tumor inoculations.
Human sIL2R measurement
The concentration of human soluble interleukin-2 receptor (sIL2R) in
mouse serum was measured by enzyme-linked immunosorbent assay
using the human sIL2R immunoassay kit (R&D Systems, Inc.) according to
the manufacturer’s instructions.
Statistical analysis
The differences between groups regarding the tumor necrosis area,
vascular number, percentage of lymphoma cells in mouse spleen cell
suspensions and human sIL2R concentrations in mouse serum were
examined with the Mann–Whitney U test. All analyses were performed
with SPSS Statistics 17.0 (SPSS Inc., Chicago, IL, USA). In this study, Po0.05
was considered signiﬁcant.
RESULTS
VEGF-A expression in DLBCL
VEGF-A expression by DLBCL cells in the lymph node lesions
according to GCB or non-GCB phenotypes are shown in Figure 1a.
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ﬁed by VEGF-A expression are shown in Figure 1b. Differences in
VEGF-A expression levels between the two DLBCL groups (GCB
versus non-GCB) did not achieve signiﬁcance (Fisher’s exact test).
Establishment of the primary DLBCL cell-bearing NOG mouse
model
The macroscopic appearance of a primary DLBCL cell-bearing
NOG mouse is shown in Figure 2a, demarcating the i.p. mass and
splenomegaly by thin white dotted lines. Flow cytometric analysis
demonstrated that the mass mainly consisted of human cells
expressing CD19 and CD25 (Figure 2b). Immunopathological
analysis revealed that it consisted of large atypical cells with
irregular and pleomorphic nuclei, and blood vessels. The cells
were CD20þ, but CD3-negative (Figure 2c). These ﬁndings are
consistent with DLBCL. The cells were in addition positive for
CD25 and negative for EBER (data not shown). VEGF expression
was 1þ positive. The DLBCL cells were also positive for MUM1/
IRF4, but negative for CD10 and BCL-6 (data not shown), and
were thus classiﬁed as non-GCB phenotype. These immuno-
pathological ﬁndings on the NOG DLBCL cells were identical to
those of the donor DLBCL.
Blood vessels in the tumor tissue were stained by anti-a-SMA
Ab (Figure 2c). Vascular endothelial cells in the tumor tissue were
stained by anti-von Willebrand Factor Ab, but not by anti-CD31
mAb (data not shown). These results indicated that blood vessels
in the tumor originated from the mouse, because anti-a-SMA and
von Willebrand Factor Ab used in the present study recognized
the corresponding protein derived from both human and mice,
whereas the anti-CD31 mAb recognized the corresponding
human but not murine protein (data not shown).
DLBCL cell inﬁltration into spleen, liver and bone marrow was
seen both by ﬂow cytometry (Figure 2d, upper panels) and
pathological analyses (Figure 2d, lower panels).
The tumor cells recovered from mice receiving the primary
lymphoma cells were serially i.p. transplanted into other NOG
mice. This procedure of transfer from mouse to mouse was
repeated successfully until at least the ﬁfth passage. The
macroscopic features of the animals and the immunopathological
ﬁndings for the tumor changed little through these serial
passages. We could passage tumor cells that had been kept
frozen until use, as well as those freshly isolated (data not shown).
In contrast, these DLBCL cells could not be maintained in vitro in
culture (data not shown).
VEGF-A, VEGF-R1 and -R2 expression in DLBCL cell lines
VEGF-A mRNA expression was detected in all eight DLBCL cell lines
tested and in NOG DLBCL cells from i.p. masses (Figure 3a, left
panel). VEGF-R1 mRNA expression was present only in two (OCI-
Ly19 and Toledo) of the DLBCL cell lines and in the NOG DLBCL
cells (Figure 3a, right panel). No VEGF-R2 mRNA expression was
detected in any of the eight DLBCL cell lines tested, or in the NOG
DLBCL cells (data not shown). Flow cytometry demonstrated that
VEGF-R1 protein was also expressed in the two lines with mRNA
(OCI-Ly19 and Toledo, Figure 3b), consistent with the results from
reverse transcription PCR. VEGF-R1 expression in NOG DLBCL cells
as assessed by ﬂow cytometry was very weak (Figure 3b) and
VEGF-R2 was not expressed at all in any of the DLBCL cell lines
tested, or in NOG DLBCL cells (data not shown), also consistent
with the reverse transcription PCR results.
Bevacizumab-mediated anti-proliferative activity against DLBCL
cells in vitro
Bevacizumab did not directly block the proliferation of OCI-Ly19
and Toledo cells in vitro, despite their expression of both VEGF-A
and VEGF-R1 (Figure 3c, upper panels). Neither did it inhibit NOG
DLBCL cells, with or without the addition of interleukin-2
(Figure 3c, lower panels).
CHOPþbevacizumab has signiﬁcantly greater therapeutic efﬁcacy
than CHOP alone in primary DLBCL cell-bearing NOG mice
Treatment with CHOPþbevacizumab resulted in an increased
percentage of tumor necrosis in the primary DLBCL cell-bearing
NOG mice (mean 12.7%, median 11.1%, range 5.2–18.7%),
compared with CHOP alone (mean 1.8%, median 1.5%, range
1.0–2.7%, P¼0.0090; Figure 4a, left panel). An example of
Figure 1. VEGF-A expression in DLBCL. (a) VEGF-A expression of DLBCL cells in the lymph node lesions according to GCB or non-GCB
phenotypes. VEGF-A expression was categorized based on the percentage of DLBCL cells stained as follows: X50%, 3þ positive; 30–49%, 2þ
positive; 10–29%, 1þ positive; o10%, negative. (b) Cases 1, 2, 3 and 4 are representative of VEGF-A negative, 1þ,2 þ and 3þ positive
categories, respectively. Photomicrographs with hematoxylin and eosin (HE; upper panels) and VEGF-A staining (lower panels) are shown.
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right panels. CHOPþbevacizumab treatment resulted in decre-
ased vasculature in the tumor tissues (41.9, 40.9, 32.5–51.3/mm
2;
(mean, median, range)), compared with CHOP alone (66.3, 71.8,
40.7–79.5/mm
2, P¼0.0472; Figure 4b, left panel). An example
of this calculation is presented in Figure 4b, right-hand panels.
Figure 2. Primary DLBCL cell-bearing NOG mouse model. (a) Macroscopic appearance of a primary DLBCL cell-bearing NOG mouse. The
intraperitoneal mass is demarcated by a thin white dotted line. (b) Human CD45þ cells in the mass determined by human CD19 and CD25
expression. (c) Immunohistochemical images of the intraperitoneal mass. (d) Human CD45þ cells of each organ determined by human CD3
and CD19 expression (upper panels). Photomicrographs with hematoxylin and eosin (HE) staining of each organ (lower panels).
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expression on cells,
22 we measured human sIL2R concentrations
as a surrogate marker reﬂecting the tumor burden of the human
CD25-expressing DLBCL. Treatment with CHOPþbevacizumab
showed signiﬁcantly greater therapeutic efﬁcacy as demonstrated
by sIL2R concentrations in the primary DLBCL cell-bearing NOG
mice (44.6, 46.1, 28.5–59.2 10
3pg/ml), compared with CHOP
alone (83.5, 78.1, 49.5–119.3 10
3pg/ml, P¼0.0283; Figure 4c).
The percentages of DLBCL cells in spleen cell suspensions of
CHOP and CHOPþbevacizumab-treated mice were 14.1%, 11.4%,
10.2–20.7%, and 26.1%, 24.6% and 19.0–34.6%, respectively.
This difference was statistically signiﬁcant (P¼0.0163; Figure 3d,
left panel). An example of the calculation is shown in Figure 4d,
right panels.
Macroscopic and microscopic ﬁndings in mice with or without
bevacizumab therapy
The appearance of primary DLBCL cell-bearing control mice
(treated with saline) or those treated with bevacizumab alone is
shown in Figure 5a, upper and lower panels, respectively. Tumor
masses are demarcated by thin white dotted lines. Photomicro-
graphs of tumor tissue from each mouse are also shown
(Figure 5b).
Figure 3. VEGF-A, VEGF-R1 and VEGF-R2 expression in DLBCL cell lines. (a) Quantitative reverse transcription (RT)-PCR analysis for VEGF-A and
VEGF-R1 in eight DLBCL cell lines, and NOG DLBCL cells from the intraperitoneal mass. (b) Flow cytometry for VEGF-R1 in DLBCL cell lines,
and NOG DLBCL cells from the intraperitoneal mass. (c) Bevacizumab has no direct anti-proliferative activity against DLBCL cell lines (OCI-Ly19
and Toledo) expressing both VEGF-A and VEGF-R1 (upper panels), and NOG DLBCL cells (lower panels), in vitro. Each result represents three
independent experiments.
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primary DLBCL cell-bearing NOG mice.
Treatment with bevacizumab alone signiﬁcantly increased the
percentage tumor necrotic area (7.5, 4.8, 2.1–18.7%) compared
with control mice (2.0, 1.7, 0.1–5.6%, P¼0.0070; Figure 6a). This
was also the case when considering vascularization of the tumor
tissues (46.2, 43.1, 33.6–60.0/mm
2, compared with 66.7, 64.8,
50.1–99.9/mm
2 in controls, P¼0.0070; Figure 6b). Treatment with
bevacizumab showed signiﬁcantly greater therapeutic efﬁcacy as
demonstrated by sIL2R concentrations in the primary DLBCL cell-
bearing NOG mice (187.6, 185.2, 5.0–350.8 10
3pg/ml), compared
with controls (459.6, 482.8, 201.5–689.5 10
3pg/ml, P¼0.0041;
Figure 6c).
The percentages of DLBCL cells in spleen cell suspensions of
bevacizumab- and saline-treated mice were 13.1, 14.6, 0.1–27.5%
and 18.7%, 18.8%, 4.0–31.7%, respectively, but this difference was
not statistically signiﬁcant (data not shown).
DISCUSSION
In the present study, we have achieved two goals: ﬁrst, to establish
a novel mouse model using NOG recipients engrafted with
primary DLBCL cells from a patient, in which the tumor cells
survive and proliferate in a murine microenvironment-dependent
manner; second, to document that bevacizumab possesses
signiﬁcant therapeutic efﬁcacy in these primary DLBCL cell-
bearing mice.
NOG mice have severe, multiple immune dysfunctions, such
that human immune cells engrafted into them retain essentially
the same functions as in humans.
23,24 In the present system,
primary DLBCL cells expressing CD19, CD20 and CD25 formed
large i.p. masses, and markedly inﬁltrated into different organs
such as spleen, liver and bone marrow. The presented features
were very similar to the donor DLBCL patient. The lymphoma cells
were positive for VEGF-A and therefore it would be expected that
the interaction of VEGF-A produced by tumor cells with VEGF-R2
Figure 4. CHOPþbevacizumab has greater therapeutic efﬁcacy than CHOP alone. (a) Area of tumor necrosis (%) of each primary DLBCL-
bearing NOG mouse. The CHOPþbevacizumab-treated mice had signiﬁcantly greater tumor necrosis than CHOP-treated mice (left panel). An
example of a calculation for tumor necrosis area (%) by means of Image J software is shown (scale bar, 200mm; right panels). (b) Numbers of
vessels (per mm
2) of each primary DLBCL-bearing NOG mouse. The CHOPþbevacizumab recipients had signiﬁcantly fewer than CHOP
recipients (left panel). An example of such a calculation by means of Image J software is shown (scale bar, 200mm; right panels). (c) Serum
sIL2R concentrations of each primary DLBCL-bearing NOG mouse. The CHOPþbevacizumab recipients had signiﬁcantly lower levels of sIL2R
than CHOP recipients. (d) Spleen-inﬁltrating tumor cells (%) of each primary DLBCL-bearing NOG mouse. The CHOPþbevacizumab recipients
had signiﬁcantly lower levels of spleen-inﬁltrating tumor cells than CHOP recipients (left panel). An example of a calculation of spleen-
inﬁltrating tumor cells (%) is shown (right panels).
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tumor angiogenesis, leading to tumor cell survival and
proliferation supported by receiving sufﬁcient nutrients and
oxygen, as reported by other investigators.
25–27 To the best of
our knowledge, this is the ﬁrst report of primary DLBCL cell-
bearing mice, in which the DLBCL cells can be maintained by serial
transplantations, but cannot be maintained in vitro in culture. This
indicates that the microenvironment is indispensable for tumor
survival; thus the present DLBCL model should better reﬂect the
human DLBCL in vivo environment, compared with other mouse
models using established tumor cell lines. Therefore, this model
should provide a powerful tool for understanding the
pathogenesis of DLBCL and, furthermore, for the one which can
be used not only to evaluate novel cytotoxic anti-DLBCL cell
agents, but also antitumor agents targeting the
microenvironment, including bevacizumab, more appropriately,
in vivo. The observed signiﬁcant antitumor activities of
bevacizumab combined with CHOP therapy were expected,
because bevacizumab is known only to be of beneﬁt to patients
with metastatic colorectal, non-small cell lung and metastatic
breast cancer, when combined with chemotherapy.
8–10 The effect
observed in mice receiving bevacizumabþCHOP, as
demonstrated by the increased tumor necrosis area and
reduced vasculature in the tumor tissue, was consistent with the
conventional antitumor mechanism of bevacizumab, which
neutralizes the human VEGF-A produced by the tumor cells, but
not murine VEGF-A.
28 It then inhibits the growth of new blood
vessels and thus starves tumor cells of necessary nutrients and
oxygen.
29 This should lead to a reduced tumor burden, as
indicated by the sIL2R concentrations measured. It was also
reported that lymphoma cell growth was promoted in an
autocrine manner via VEGF-A/VEGF-R1 or VEGF-A/VEGF-R2
Figure 5. Macroscopic and microscopic ﬁndings of mice with or without bevacizumab therapy. (a) Macroscopic appearance of mice treated
with saline (control; upper panels) or bevacizumab (lower panels). Tumor masses are demarcated by thin white dotted lines.
(b) Photomicrographs with hematoxylin and eosin (HE) staining of saline (control; upper panels) or bevacizumab-treated tumor (lower panels).
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25 but the present in vitro data did not support that
observation. In the present study, signiﬁcant effects of
bevacizumab alone were also observed, as demonstrated by the
increased area of tumor necrosis and reduced vasculature in the
tumor tissue, leading to a degree of antitumor therapeutic efﬁcacy
as demonstrated by reduced tumor burden indicated by serum
sIL2R concentrations. In contrast to combination therapy,
bevacizumab alone was not active when assessed by the
percentages of DLBCL cells in the spleen. One possible
explanation for this is that the spleen is likely to be more richly
vascularized compared with the tumor mass, and thus
bevacizumab alone has little starvation effect on the tumor cells
therein. It has been reported that VEGF-targeted therapy can
‘normalize’ the tumor vascular network and that this can lead to a
more uniform blood-ﬂow, with subsequent increased delivery of
chemotherapeutic agents.
30–32 Therefore, the tumor cells in
spleen might be efﬁciently reduced only when bevacizumab is
combined with chemotherapy.
The present study demonstrated the importance of angiogen-
esis for the pathogenesis of VEGF-expressing DLBCL. Ganjoo
et al.
33 reported that VEGF expression was detected in 42–60% of
tumor cells in DLBCL and Gratzinger et al.
34 found that 60% of
cases showed strong VEGF immunoreactivity, deﬁned as VEGF
expression in 430% of the tumor cells. These reports together
with our present study indicate that targeting angiogenesis would
be a promising strategy for at least a subgroup of DLBCL patients
whose tumors depend to a large extent on angiogenesis via VEGF
for survival and proliferation. In fact, bevacizumab as a single
agent has been reported to have modest clinical activity in
patients in the setting of relapsed aggressive non-Hodgkin
lymphoma
35 and in combination with rituximab-CHOP in ﬁrst-
line treatment.
33 However, a phase III clinical study evaluating the
efﬁcacy and safety of bevacizumab together with rituximab plus
CHOP in patients with DLBCL (MAIN trial) could not be completed
after a safety and efﬁcacy analysis of the ﬁrst 720 patients. We
believe that this result of the MAIN trial does not necessarily have
to lead to the conclusion that bevacizumab is ineffective in DLBCL.
Analogously, the epidermal growth factor receptor tyrosine kinase
inhibitor, geﬁtinib, failed to yield a signiﬁcantly improved overall
survival in patients with refractory non-small cell lung cancer,
36
but did show therapeutic beneﬁt in a subgroup of patients with
mutated epidermal growth factor receptor.
37–39 In the case of
mAb targeting the epidermal growth factor receptor, both
panitumumab and cetuximab also provide clinical beneﬁts only
to a subgroup of colorectal cancer patients with wild-type KRAS
and BRAF.
40 These ﬁndings indicate that we should develop novel
treatment strategies based on tumor biology and not on tumor
category. DLBCL is a highly heterogeneous category with respect
to biology, morphology and clinical presentation,
16 as are non-
small cell lung cancer or colorectal cancer. Therefore, further
investigations are warranted to determine which subgroups of
DLBCL patients will beneﬁt from bevacizumab therapy.
In conclusion, using NOG mice as recipients, we have
established a novel model in which primary DLBCL cells from a
patient engraft and proliferate in a murine microenvironment-
dependent manner. The present DLBCL model should more truly
reproduce the human DLBCL in vivo environment, compared with
any other current models, which use established tumor cell lines.
This is the ﬁrst report to evaluate the efﬁcacy of bevacizumab in
such a tumor microenvironment-dependent model. Bevacizumab
therapy could be a potential treatment strategy for that subgroup
of DLBCL depending to a large extent on angiogenesis via VEGF
for tumor survival and proliferation.
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